Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
Status:
Terminated
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
This is a phase I dose escalation study to estimate the maximum tolerated dose (MTD) of the
novel combination of Arsenic, Ascorbic Acid and Velcade, followed by a phase II study
conducted using the MTD estimated from the phase I portion.